Commercial A year after Vertex’s big launch, pain drug research faces a pivotal moment BioPharma DiveJournavx revived an area of development long considered a graveyard.Pain & AnaesthesiaRead full story pharminent May 12, 2026 (Last updated: May 16, 2026) BioPharma Dive Journavx revived an area of development long considered a graveyard. Pain & Anaesthesia Read full story Post navigation Previous: FDA weighs drug repurposing pathway for underserved diseasesNext: Novo says high-dose Wegovy can cause 28% weight loss Related Stories Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026 Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026
